NHSE commissioned

To be used in line with NICE TA 471. Specialist initiation, and transfer prescribing to GP using RICaD (in development).

For existing patients only

• NICE TA 1097 Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable | Guidance | NICE

For all other indications. The APC's view is that on clinical grounds, the status for certain indications approved by APC should be amber, supported by an ESCA. However, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain red (ESCAs to be developed). 

For hospital use only

Unlicensed special

Hospital use only

Short term use only

Equivalent to Diprobase® 
OTC preparation: A prescription for an over the counter emollient for treatment of mild dry skin should not routinely be offered in primary care  -  appropriate for self-care.